$SESN FDA Meeting on the May 20

Sine the 13th may when President and CEO DR Thomas Cannell conducted the company's earnings call, investors are buoyed by what he had to say and the future prospects, with upcoming meetings with the FDA this could be a blowout stock in the weeks to come.
Average analyst estimate BUY
Average analysts price target $3.50
Company Description
Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells.

Komen:

Komen:

HOPE YOU BENEFITED FROM THIS MOVE